Using Soluble CD59 to Treat Age-Related Macular Degeneration
Author Information
Author(s): Siobhan M. Cashman, Kasmir Ramo, Rajendra Kumar-Singh, Alfredo Fusco
Primary Institution: Tufts University School of Medicine
Hypothesis
Can soluble CD59 inhibit the formation of choroidal neovascularization in a model of age-related macular degeneration?
Conclusion
The study found that soluble CD59 can significantly reduce choroidal neovascularization in mice, suggesting it may be a potential therapy for age-related macular degeneration.
Supporting Evidence
- Soluble CD59 significantly reduced the size of choroidal neovascularization spots in treated mice.
- Delivery of soluble CD59 via gene therapy showed potential for treating both wet and dry forms of age-related macular degeneration.
- MAC deposition was significantly reduced in eyes treated with soluble CD59.
Takeaway
Researchers found that a special protein called soluble CD59 can help protect the eyes from a condition that causes vision loss in older people.
Methodology
The study used adenovirus and adeno-associated virus vectors to deliver soluble CD59 to mouse eyes and measured the effects on choroidal neovascularization.
Limitations
The study was conducted in mice, and results may not directly translate to humans; also, the small size of mouse eyes may complicate injections.
Participant Demographics
C57BL/6J mice were used in the experiments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website